YOLFTbeta
Sinew Pharma Inc.

Sinew Pharma Inc.

6634 · TWO · Healthcare / Biotechnology

59.90TWD-0.40 (-0.66%)

Price History

Full chart

Market Stats

Previous Close60.30
Open60.40
Day Range58.80 – 60.40
52-Week Range29.05 – 85.00
Volume42.60K
Market Cap4.72B
P/E (TTM)0.00
Forward P/E0.00
EPS-1.67
Dividend Yield0.00%
Beta0.59
50-Day Avg57.74
200-Day Avg49.95

About

Sinew Pharma Inc., a biopharmaceutical company, focuses on the research, development, and sale of drugs for the treatment of hepatotoxicity-free acetaminophen and fatty liver diseases. The company's products include SNP-610 drug, which is in Phase IIa clinical trial and SNP-630 drug, which is in Phase II clinical trial for treating patients with non-alcoholic steatohepatitis in Taiwan. It is also developing SNP-810 is in phase II clinical trial for use in pain relief and fever reduction; SNP-820 is in Phase II clinical trial for antidote for acetaminophen poisoning, and SNP-830 and SNP-840, which in pre-clinical trial are used as hepatotoxicity-free analgesic medicines in the United States. Sinew Pharma Inc. was founded in 2014 and is based in Taipei City, Taiwan.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEODr. Kai-Min Chu M.D., Ph.D.
  • Employees52
  • HeadquartersC516, Building C, Taipei, Taiwan, 11571, Taiwan
  • Websitehttps://www.sinewpharma.com

Leadership

  • Dr. Kai-Min Chu M.D., Ph.D.Chairman & CEO
  • Mr. Cheng-Hui Hsiung Ph.D.COO & Director
  • Ms. Tzu-Wen ChenChief Financial Officer & Accounting Supervisor
  • Ms. Hsin-Tien HoChief Technology Officer

Financials

Income Statement

Currency: TWD2019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue-462.00K6.23M328.00K0047.00K
Growth (%)--+1248.27%-94.73%-100.00%--
Cost of Revenue-138.00K1.14M38.00K28.98M30.31M10.00K
Gross Profit-324.00K5.09M290.00K-28.98M-30.31M37.00K
Gross Margin-70.13%81.75%88.41%--78.72%
Operating Expense-84.43M99.51M148.72M157.27M138.56M140.16M
Operating Income-76.05M-84.11M-94.42M-148.43M-186.25M-168.86M-140.13M
Operating Margin--18204.76%-1515.81%-45252.44%---298140.43%
EBITDA-57.79M-59.88M-68.78M-117.09M-163.63M-119.65M-103.76M
EBITDA Margin--12961.26%-1104.27%-35698.78%---220759.57%
Net Income-76.22M-82.01M-91.58M-140.18M-170.92M-150.37M-123.75M
Net Income Margin--17751.30%-1470.14%-42737.80%---263287.23%
R&D60.29M66.70M72.75M114.62M133.46M113.59M97.47M
R&D as % of Total Revenue-14438.31%1167.84%34944.51%--207391.49%
Interest Expense176.00K274.00K146.00K275.00K776.00K414.00K657.00K
Interest Expense % of Total Revenue-59.31%2.34%83.84%--1397.87%

Balance Sheet

Currency: TWD2019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets420.78M453.16M1.58B1.49B1.36B1.23B1.13B
Total Liabilities252.01M17.40M15.96M28.66M39.71M28.88M36.42M
Total Equity168.77M435.76M1.57B1.46B1.32B1.20B1.09B
Cash252.72M46.82M551.17M246.68M166.81M41.39M25.27M
Total Debt5.18M3.34M1.05M7.54M9.28M2.82M-
Net Debt-247.54M-43.48M-550.12M-239.13M-157.53M-38.57M-

Cash Flow

Currency: TWD2019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-58.73M-59.26M-57.32M-93.76M-118.05M-106.08M-95.30M
Investing Cash Flow34.01M-256.72M-648.56M-221.15M26.20M-16.69M-
Financing Cash Flow235.65M110.09M1.21B10.41M11.98M-2.65M-
Capital Expenditure6.66M2.69M5.87M5.88M7.45M1.33M1.87M
Free Cash Flow-65.40M-61.96M-63.18M-99.64M-125.50M-107.41M-97.17M
FCF to OCF111.34%104.55%110.24%106.28%106.31%101.25%101.96%

Key Statistics & Ratios

Market Cap4.72B
Enterprise Value3.29B
Trailing P/E0.00
Forward P/E0.00
Price / Sales100411.20
Price / Book4.12
EPS-1.67
Book Value14.55
Revenue (TTM)47.00K
Gross Profit (TTM)37.00K
EBITDA-127.75M
Profit Margin0.00%
Operating Margin-283142.55%
Return on Equity-10.85%
Return on Assets-7.40%
Shares Outstanding71.29M
Shares Float43.02M
Beta0.59
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%